share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Topper David Joseph

SEC announcement ·  Apr 12 08:36
Summary by Futu AI
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.